Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ecopia BioSciences, Inc.
Clinical trial application filed for ECO-4601, small molecule with potential for treating cancer
February 5th, 2006
Ecopia BioSciences, Inc., (EIA) has filed a clinical trial application (CTA) for ECO-4601, a small molecule that has potential for the treatment of specific cancers such as primary brain tumors, breast cancer, and prostate cancer. A CTA filing is the equivalent of an investigational new drug application in the United States and is a request to the regulatory authorities in Canada to seek approval to conduct a clinical study in humans. Upon approval of the CTA by the Therapeutic Product directorate of Health Canada, Ecopia is proposing to conduct a phase I clinical trial with up to 30 patients who will be recruited at the clinical research unit of the...
Source: Women's Health Law Weekly (2006-02-05)
|
